In summary, our MD simulations and docking analysis provide details of the structural consequence and their interaction with AML inhibitors which are useful for further development of novel inhibitors to overcome the drug resistance conferred by the D835A/E/F/G/H/I/N/V/Y, FLT3 mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.